{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:28:18Z","timestamp":1776324498790,"version":"3.50.1"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> To investigate the association between statin use and risk of gout in patients with hyperlipidemia.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> In this population-based retrospective cohort study, patients \u226520\u00a0years and diagnosed as having incident hyperlipidemia between 2001 and 2012 were identified from the 2000 Longitudinal Generation Tracking Database in Taiwan. Regular statin users (incident statin use, having 2 times and \u226590\u00a0days of prescription for the first year) and two active comparators [irregular statin use and other lipid-lowering agent (OLLA) use] were compared; the patients were followed up until the end of 2017. Propensity score matching was applied to balance potential confounders. Time-to-event outcomes of gout and dose- and duration-related associations were estimated using marginal Cox proportional hazard models.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Regular statin use non-significantly reduced gout risk compared with irregular statin use (aHR, 0.95; 95% CI, 0.90\u20131.01) and OLLA use (aHR, 0.94; 95% CI, 0.84\u20131.04). However, a protective effect was noted for a cumulative defined daily dose (cDDD) of &amp;gt;720 (aHR, 0.57; 95% CI, 0.47\u20130.69 compared with irregular statin use and aHR, 0.48; 95% CI, 0.34\u20130.67 compared with OLLA use) or a therapy duration of &amp;gt;3\u00a0years (aHR, 0.76; 95% CI, 0.64\u20130.90 compared with irregular statin use and aHR, 0.50; 95% CI, 0.37\u20130.68 compared with OLLA use). Dose- and duration-dependent associations were consistent in the 5-year sensitivity analyses.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Although statin use was not associated with a reduction in gout risk, the protective benefit was observed in those receiving higher cumulative doses or with a longer therapy duration.<\/jats:p>","DOI":"10.3389\/fphar.2023.1096999","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T06:49:44Z","timestamp":1676443784000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Association between statin use and the risk of gout in patients with hyperlipidemia: A population-based cohort study"],"prefix":"10.3389","volume":"14","author":[{"given":"Guan-Ling","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiu-Chen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiu-Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph Jordan","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Hsuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2217\/cer-2020-0013","article-title":"Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants","volume":"9","author":"Allan","year":"2020","journal-title":"J. Comp. Eff. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: Reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.phrs.2018.08.014","article-title":"Effect of statins on toll-like receptors: A new insight to pleiotropic effects","volume":"135","author":"Bahrami","year":"2018","journal-title":"Pharmacol. Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/bor.0000000000000028","article-title":"Definition of hyperuricemia and gouty conditions","volume":"26","author":"Bardin","year":"2014","journal-title":"Curr. Opin. Rheumatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/imr.12833","article-title":"Urate-induced immune programming: Consequences for gouty arthritis and hyperuricemia","volume":"294","author":"Cab\u0103u","year":"2020","journal-title":"Immunol. Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/ene.14542","article-title":"Pioglitazone and statins lower incidence of Parkinson disease in patients with diabetes mellitus","volume":"28","author":"Chang","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s10067-011-1802-6","article-title":"Gender-specific risk factors for incident gout: A prospective cohort study","volume":"31","author":"Chen","year":"2012","journal-title":"Clin. Rheumatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/bjd.13850","article-title":"Adherence to statins and the risk of psoriasis: A population-based cohort study","volume":"173","author":"Chodick","year":"2015","journal-title":"Br. J. Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/2047487313514895","article-title":"Increased cardiovascular mortality associated with gout: A systematic review and meta-analysis","volume":"22","author":"Clarson","year":"2015","journal-title":"Eur. J. Prev. Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1097\/mib.0000000000000640","article-title":"Potential immunomodulatory effects of statins in inflammatory bowel disease","volume":"22","author":"C\u00f4t\u00e9-Daigneault","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1002\/ibd.21822","article-title":"Statins are associated with reduced use of steroids in inflammatory bowel disease: A retrospective cohort study","volume":"18","author":"Crockett","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/s0140-6736(21)00569-9","volume":"397","author":"Dalbeth","year":"2021","journal-title":"Gout. Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1136\/annrheumdis-2016-210936","article-title":"Pattern of risks of systemic lupus erythematosus among statin users: A population-based cohort study","volume":"76","author":"De Jong","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","article-title":"Global epidemiology of gout: Prevalence, incidence, treatment patterns and risk factors","volume":"16","author":"Dehlin","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"107614","DOI":"10.1016\/j.pharmthera.2020.107614","article-title":"Statins and autoimmunity: State-of-the-art","volume":"214","author":"Dehnavi","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s40265-016-0591-2","article-title":"Impact of statin therapy on plasma uric acid concentrations: A systematic review and meta-analysis","volume":"76","author":"Derosa","year":"2016","journal-title":"Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/jcph.1989","article-title":"Use of propensity scoring and its application to real-world data: Advantages, disadvantages, and methodological objectives explained to researchers without using mathematical equations","volume":"62","author":"Franchetti","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1146\/annurev-immunol-041015-055539","article-title":"Crystal Formation in inflammation","volume":"34","author":"Franklin","year":"2016","journal-title":"Annu. Rev. Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1177\/1074248419857071","article-title":"Effectiveness of statins as primary prevention in people with gout: A population-based cohort study","volume":"24","author":"Garcia-Gil","year":"2019","journal-title":"J. Cardiovasc Pharmacol. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10753-018-0907-3","article-title":"Statins inhibit cytokines in a dose-dependent response in patients with systemic sclerosis","volume":"42","author":"Gon\u00e7alves","year":"2019","journal-title":"Inflammation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41577-019-0215-7","article-title":"DAMP-sensing receptors in sterile inflammation and inflammatory diseases","volume":"20","author":"Gong","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/nrd1901","article-title":"Anti-inflammatory effects of statins: Clinical evidence and basic mechanisms","volume":"4","author":"Jain","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"B23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/aje\/kwv445","article-title":"Comparison of statistical approaches for dealing with immortal time bias in drug effectiveness studies","volume":"184","author":"Karim","year":"2016","journal-title":"Am. J. Epidemiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.semarthrit.2018.03.007","article-title":"Statin use and mortality in gout: A general population-based cohort study","volume":"48","author":"Keller","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"B25","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s12026-013-8409-8","article-title":"Statins and autoimmunity","volume":"56","author":"Khattri","year":"2013","journal-title":"Immunol. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12016-020-08791-9","article-title":"Anti-inflammatory action of statins in cardiovascular disease: The role of inflammasome and toll-like receptor pathways","volume":"60","author":"Koushki","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13075-015-0522-8","article-title":"Epidemiology and management of gout in taiwan: A nationwide population study","volume":"17","author":"Kuo","year":"","journal-title":"Arthritis Res. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","article-title":"Global epidemiology of gout: Prevalence, incidence and risk factors","volume":"11","author":"Kuo","year":"","journal-title":"Nat. Rev. Rheumatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3904\/kjim.2018.205","article-title":"Clinical features and recurrent attack in gout patients according to serum urate levels during an acute attack","volume":"35","author":"Lee","year":"2020","journal-title":"Korean J. Intern Med."},{"key":"B30","article-title":"Exposure definition and measurement","volume-title":"Developing a protocol for observational comparative effectiveness research: A user's guide","author":"Lee","year":"2013"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.2147\/copd.S267017","article-title":"Association between use of antihyperlipidemic agents and chronic obstructive pulmonary disease in patients with hyperlipidemia: A population-based retrospective cohort study","volume":"15","author":"Lei","year":"2020","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e2018062","DOI":"10.4178\/epih.e2018062","article-title":"Data resource profile: The national Health insurance research database (NHIRD)","volume":"40","author":"Lin","year":"2018","journal-title":"Epidemiol. Health"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1136\/annrheumdis-2017-211253","article-title":"Survival benefit of statin use in ankylosing spondylitis: A general population-based cohort study","volume":"76","author":"Oza","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.intimp.2019.05.006","article-title":"NLRP3 inflammasome as a treatment target in atherosclerosis: A focus on statin therapy","volume":"73","author":"Parsamanesh","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"107278","DOI":"10.1016\/j.intimp.2020.107278","article-title":"Pitavastatin ameliorates autoimmune neuroinflammation by regulating the Treg\/Th17 cell balance through inhibition of mevalonate metabolism","volume":"91","author":"Prado","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.chest.2017.02.002","article-title":"The impact of statin drug use on all-cause mortality in patients with copd: A population-based cohort study","volume":"152","author":"Raymakers","year":"2017","journal-title":"Chest"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e000046","DOI":"10.1136\/rmdopen-2015-000046","article-title":"Why does the gout attack stop? A roadmap for the immune pathogenesis of gout","volume":"1","author":"Schett","year":"2015","journal-title":"RMD Open"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3899\/jrheum.080938","article-title":"Serum urate during acute gout","volume":"36","author":"Schlesinger","year":"2009","journal-title":"J. Rheumatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1136\/annrheumdis-2015-207714","article-title":"Statin use and mortality in rheumatoid arthritis: A general population-based cohort study","volume":"75","author":"Schoenfeld","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/pds.1062","article-title":"An application of propensity score matching using claims data","volume":"14","author":"Seeger","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/clep.S178723","article-title":"Observational studies of treatment effectiveness: Worthwhile or worthless?","volume":"11","author":"Sharma","year":"2019","journal-title":"Clin. Epidemiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrrheum.2017.155","article-title":"Inflammation in gout: Mechanisms and therapeutic targets","volume":"13","author":"So","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.coph.2018.01.001","article-title":"Statins in the treatment of COPD and asthma-where do we stand?","volume":"40","author":"So","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/bor.0000000000000691","article-title":"Comorbidities in gout and hyperuricemia: Causality or epiphenomena?","volume":"32","author":"Sumpter","year":"2020","journal-title":"Curr. Opin. Rheumatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1002\/art.39774","article-title":"Statins and risk of rheumatoid arthritis: A nested case-control study","volume":"68","author":"Tascilar","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/ajg.2016.233","article-title":"Statins associated with decreased risk of new onset inflammatory bowel disease","volume":"111","author":"Ungaro","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1136\/annrheumdis-2018-214656","article-title":"mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy?","volume":"78","author":"Vazirpanah","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/2040622315596119","article-title":"The effect of angiotensin II receptor blockers on hyperuricemia","volume":"6","author":"Wolff","year":"2015","journal-title":"Ther. Adv. Chronic Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000182258","article-title":"Psoriasis in France and associated risk factors: Results of a case-control study based on a large community survey","volume":"218","author":"Wolkenstein","year":"2009","journal-title":"Dermatology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2015.08.030","article-title":"Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study","volume":"243","author":"Yu","year":"2015","journal-title":"Atherosclerosis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/1756-185x.13266","article-title":"Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan","volume":"21","author":"Yu","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/imm.12902","article-title":"Immune modulatory effects of statins","volume":"154","author":"Zeiser","year":"2018","journal-title":"Immunology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3390\/biom11020280","article-title":"Why does hyperuricemia not necessarily induce gout?","volume":"11","author":"Zhang","year":"2021","journal-title":"Biomolecules"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/aje\/kwi307","article-title":"Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: A comparison of methods","volume":"162","author":"Zhou","year":"2005","journal-title":"Am. J. Epidemiol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1096999\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T06:49:49Z","timestamp":1676443789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1096999\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":55,"alternative-id":["10.3389\/fphar.2023.1096999"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1096999","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]},"article-number":"1096999"}}